These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 17919101

  • 1. Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy.
    Poveda E, Briz V, Paraskevis D, Barreiro P, Hatzakis A, Soriano V.
    AIDS Res Hum Retroviruses; 2007 Sep; 23(9):1078-82. PubMed ID: 17919101
    [Abstract] [Full Text] [Related]

  • 2. Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy.
    Charpentier C, Jenabian MA, Piketty C, Karmochkine M, Tisserand P, Laureillard D, Bélec L, Si-Mohamed A, Weiss L.
    Scand J Infect Dis; 2011 May; 43(5):373-9. PubMed ID: 21341978
    [Abstract] [Full Text] [Related]

  • 3. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
    Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, Bagnarelli P, Lazzarin A, Clementi M.
    New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
    [Abstract] [Full Text] [Related]

  • 4. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.
    Bienvenu B, Krivine A, Rollot F, Pietri MP, Lebault V, Meritet JF, Guerin C, Spiridon G, Salmon D, Guillevin L, Lebon P, Launay O.
    J Med Virol; 2006 Oct; 78(10):1312-7. PubMed ID: 16927284
    [Abstract] [Full Text] [Related]

  • 5. Short communication: high polymorphism rates in the HR1 and HR2 gp41 and presence of primary resistance-related mutations in HIV type 1 circulating in Brazil: possible impact on enfuvirtide efficacy.
    Teixeira C, de Sá-Filho D, Alkmim W, Janini LM, Diaz RS, Komninakis S.
    AIDS Res Hum Retroviruses; 2010 Mar; 26(3):307-11. PubMed ID: 20334566
    [Abstract] [Full Text] [Related]

  • 6. Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen.
    Cabrera C, Marfil S, García E, Martinez-Picado J, Bonjoch A, Bofill M, Moreno S, Ribera E, Domingo P, Clotet B, Ruiz L.
    AIDS; 2006 Oct 24; 20(16):2075-80. PubMed ID: 17053353
    [Abstract] [Full Text] [Related]

  • 7. Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.
    Marcial M, Lu J, Deeks SG, Ziermann R, Kuritzkes DR.
    J Clin Microbiol; 2006 Sep 24; 44(9):3384-7. PubMed ID: 16954280
    [Abstract] [Full Text] [Related]

  • 8. Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide.
    Loutfy MR, Raboud JM, Montaner JS, Antoniou T, Wynhoven B, Smaill F, Rouleau D, Gill J, Schlech W, Brumme ZL, Mo T, Gough K, Rachlis A, Harrigan PR, Walmsley SL.
    Antiviral Res; 2007 Jul 24; 75(1):58-63. PubMed ID: 17196268
    [Abstract] [Full Text] [Related]

  • 9. gp41 sequence variability in HIV type 1 non-B subtypes infected patients undergoing enfuvirtide pressure.
    D'Arrigo R, Ciccozzi M, Gori C, Montieri S, Aquaro S, Bellagamba R, Boumis E, Di Perri G, Pizzi D, Antinori A, Rezza G, Perno CF.
    AIDS Res Hum Retroviruses; 2007 Oct 24; 23(10):1296-302. PubMed ID: 17961119
    [Abstract] [Full Text] [Related]

  • 10. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy.
    Poveda E, Rodés B, Lebel-Binay S, Faudon JL, Jimenez V, Soriano V.
    J Clin Virol; 2005 Dec 24; 34(4):295-301. PubMed ID: 16286053
    [Abstract] [Full Text] [Related]

  • 11. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.
    Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, Bagnarelli P, Lazzarin A, Clementi M.
    Antimicrob Agents Chemother; 2004 Sep 24; 48(9):3253-9. PubMed ID: 15328081
    [Abstract] [Full Text] [Related]

  • 12. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
    Deeks SG, Lu J, Hoh R, Neilands TB, Beatty G, Huang W, Liegler T, Hunt P, Martin JN, Kuritzkes DR.
    J Infect Dis; 2007 Feb 01; 195(3):387-91. PubMed ID: 17205477
    [Abstract] [Full Text] [Related]

  • 13. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
    Labrosse B, Morand-Joubert L, Goubard A, Rochas S, Labernardière JL, Pacanowski J, Meynard JL, Hance AJ, Clavel F, Mammano F.
    J Virol; 2006 Sep 01; 80(17):8807-19. PubMed ID: 16912327
    [Abstract] [Full Text] [Related]

  • 14. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment.
    Aquaro S, D'Arrigo R, Svicher V, Perri GD, Caputo SL, Visco-Comandini U, Santoro M, Bertoli A, Mazzotta F, Bonora S, Tozzi V, Bellagamba R, Zaccarelli M, Narciso P, Antinori A, Perno CF.
    J Antimicrob Chemother; 2006 Oct 01; 58(4):714-22. PubMed ID: 16891628
    [Abstract] [Full Text] [Related]

  • 15. Enfuvirtide is active against HIV type 1 group O.
    Poveda E, Barreiro P, Rodés B, Soriano V.
    AIDS Res Hum Retroviruses; 2005 Jun 01; 21(6):583-5. PubMed ID: 15989465
    [Abstract] [Full Text] [Related]

  • 16. Virological fitness of HIV in patients with resistance to enfuvirtide.
    Chibo D, Roth N, Roulet V, Skrabal K, Gooey M, Carolan L, Nicholls J, Papadakis A, Birch C.
    AIDS; 2007 Sep 12; 21(14):1974-7. PubMed ID: 17721108
    [Abstract] [Full Text] [Related]

  • 17. Enfuvirtide (T-20) resistance-related mutations in HIV type 1 subtypes B, C, and F isolates from Brazilian patients failing HAART.
    Oliveira AC, Martins AN, Pires AF, Arruda MB, Tanuri A, Pereira HS, Brindeiro RM.
    AIDS Res Hum Retroviruses; 2009 Feb 12; 25(2):193-8. PubMed ID: 19239358
    [Abstract] [Full Text] [Related]

  • 18. Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure.
    Poveda E, Rodés B, Labernardière JL, Benito JM, Toro C, González-Lahoz J, Faudon JL, Clavel F, Schapiro J, Soriano V.
    J Med Virol; 2004 Sep 12; 74(1):21-8. PubMed ID: 15258964
    [Abstract] [Full Text] [Related]

  • 19. Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K).
    Tolstrup M, Selzer-Plön J, Laursen AL, Bertelsen L, Gerstoft J, Duch M, Pedersen FS, Ostergaard L.
    AIDS; 2007 Feb 19; 21(4):519-21. PubMed ID: 17301572
    [No Abstract] [Full Text] [Related]

  • 20. Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering?
    Morse C, Maldarelli F.
    J Infect Dis; 2007 Feb 01; 195(3):318-21. PubMed ID: 17205468
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.